



Supplemental Figure 1.

A.




(A) *IDH2* Mutational Burden among those with (N=3) or without (N=6) subsequent relapse.

**B.**



(B) Change in *IDH2* Mutational Burden from pre-transplant to time of maintenance initiation and subsequent relapse for patients with both data points available (N=8). VAF: Variant allelic fraction.

**Supplemental Figure 2.**



There was no significant difference between baseline plasma 2-HG and subsequent relapse for patients with patients with R140 versus R172 *IDH2* mutations.

## Supplemental Table

Patient #	Pre-HCT Marrow IDH2 VAF (%)	Pre-HCT Marrow Blasts (%)	Pre-Treatment Marrow IDH2 VAF (%)	Pre-Treatment Marrow Blasts (%)
2	25.7	0.5		
3			0.135	1.0
4			0.092	0
5	0.282	1.0	0.392	4.0
6	11.5	2.0	0.631	1.0
7			0	1.6
8			0	0.5
9	0	1.0	0	3.0
10	0.267	3.0	0	2.0
14			0	0
15	3.4	3.0	0.9	1.0
17	0	0	0	2.0
18	3.6	3.0	0	0
20	0	1.0	0	1.0
21			7.01	0